April 25, 2026Open Access

F-40 | Superior safety profile of Ultra-Short Term DAPT Followed by P2Y12 Monotherapy compared to Long-Term DAPT in ACS: A Meta-analysis of Randomized Trials

PPParth PatelWorcester Polytechnic Institute ADAditya DesaiUniversity of California, Riverside KPKarnik PatelRegional Medical Center

Key Result

Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy has a superior safety profile compared to 12-month DAPT in patients with acute coronary syndrome.

Key Points

This research aims to evaluate the safety of ultra-short term DAPT followed by P2Y12 monotherapy compared to long-term DAPT in ACS patients.
Conducted a systematic review and meta-analysis of randomized controlled trials (RCTs).
Compared outcomes of ultra-short term DAPT (≤1 month) to long-term DAPT (12 months).
Ultra-short term DAPT significantly reduced bleeding risk when followed by P2Y12 monotherapy.
Long-term DAPT showed higher bleeding incidence than the ultra-short term approach.

Structured PICO

Does ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy improve the overall safety profile compared to long term (12 months) DAPT in patients with ACS following PCI?

Population

Patients with acute coronary syndrome (ACS) following percutaneous intervention (PCI)

Intervention

Ultra-short term (≤1 month) dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy

Comparator

Long term (12 months) dual antiplatelet therapy (DAPT)

Outcome

Overall safety profile (bleeding risk)safety

Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy appears to offer a superior safety profile compared to standard 12-month DAPT in ACS patients undergoing PCI.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Short term dual antiplatelet therapy (DAPT) may reduce bleeding risk following percutaneous intervention (PCI) in acute coronary syndrome (ACS) but the overall safety profile of ultra-short term (≤1 month) DAPT followed by P2Y12 monotherapy compared to long term (12 months) DAPT remains uncertain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to bridge evidence gap.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Patel et al. (Wed,) reported a other. Ultra-short term DAPT (≤1 month) followed by P2Y12 monotherapy has a superior safety profile compared to 12-month DAPT in patients with acute coronary syndrome.

synapsesocial.com/papers/69ec5b0688ba6daa22dac8f9 https://doi.org/https://doi.org/10.1016/j.jscai.2026.105152

AI에게 질문

Bookmark

View Full Paper